**EFFICACY OF RESPONSE-GUIDED PEGYLATED INTERFERON AND RIBAVIRIN THERAPY FOR PEOPLE WHO INJECT DRUGS WITH HCV GENOTYPE 2/3 INFECTION: THE ACTIVATE STUDY**

Grebely J1, Dalgard O2, Conway B3, Foster GR4, Bruggmann P5, Hajarizadeh B1, Backmund M6, Robaeys G7,8,9, Swan T10, Amin J1, Marks P1, Quiene S1, Weltman M11, Shaw D12, Dunlop A13, Hellard M14, Bruneau J15, Bourgeois S16, Staehelin C17, and Dore GJ1 on behalf of the ACTIVATE Study Group

1The Kirby Institute, UNSW Australia, Sydney, Australia, 2Akershus University Hospital, Oslo, Norway, 3Vancouver Infectious Diseases Center, Vancouver, Canada, 4The Liver Unit, Queen Marys University of London, London, United Kingdom, 5Arud Centres for Addiction Medicine, Zurich, Switzerland, 6Ludwig Maximilians-University Munich, Munich, Germany, 7Department of Gastroenterology and Hepatology, Ziekenhuis Oost Limburg, Genk, 8Department of Hepatology, UZ Leuven, Leuven, 9UHasselt, Hasselt, Belgium, 10Treatment Action Group, New York, United States, 11Nepean Hospital, Sydney, 12Royal Adelaide Hospital, Adelaide, 13School of Medicine and Public Health, University of Newcastle, Newcastle, 14Burnet Institute, Melbourne, Australia, 15Universite de Montreal, Montreal, Canada, 16Stuivenberg ZNA, Antwerp, Belgium, 17Division of Infectious Diseases, University Hospital and University of Bern, Bern, Switzerland

**Introduction:** Despite guidelines advocating for HCV treatment among PWID, treatment uptake is low. The aim of this study was to evaluate response-guided pegylated interferon alfa-2b (PEG-IFN) and ribavirin (RBV) treatment for chronic HCV genotypes 2/3 (G2/3) among recent PWID.

**Methods:** Participants with chronic HCV G2/3 and recent injecting drug use (previous 12 weeks) or receiving opioid substitution treatment (OST) were recruited between 2012 and 2014. Participants received directly observed PEG-IFN (1.5 µg/kg/week) and self-administered RBV (800-1400 mg daily, weight-based). Participants with a rapid virological response (RVR) received 12 weeks (shortened duration) and those without RVR received 24 weeks (standard duration) therapy. The primary endpoint was sustained virological response at 12 weeks (SVR12) by intention to treat.

**Results:** 93 participants initiated treatment (mean age 42 years; 82% male; 87% HCV G3), with 25% (n=23) receiving OST with no recent injecting, 17% (n=16) receiving OST with recent injecting, and 58% (n=58%) not receiving OST with recent injecting. Sixty-six percent (n=61) achieved RVR and received shortened treatment, while 28% (n=26) did not achieve RVR and received standard treatment. SVR12 was 62% (58/93). Therapy was discontinued prior to week four in 6% (n=6). SVR12 was 79% (48/61) in those with RVR (shortened treatment) compared to 38% (10/26) in those without RVR (standard treatment). SVR was similar among OST non-injecting, OST injecting and non-OST injecting groups (68% vs. 63% vs. 86%, P=0.446). In multivariate analyses, RVR was the only factor associated with SVR (OR=7.51; 95% CI: 2.38, 23.73; P<0.001).

**Conclusion:** Among PWID with chronic HCV G2/3, on-treatment RVR allowed shortened treatment duration and remained a strong predictor of SVR. Injecting drug use at baseline was not associated with reduced response to therapy. These data suggest that among PWID with chronic HCV G2/3 and an RVR, shortened PEG-IFN/RBV treatment may be a feasible strategy.

**Disclosure of Interest Statement:** The Kirby Institute is funded by the Australian Government Department of Health and Ageing. This study was funded by Merck, Sharp & Dohme.